JP2022512796A - Ｉ型インターフェロンシグネチャー及び使用方法 - Google Patents

Ｉ型インターフェロンシグネチャー及び使用方法 Download PDF

Info

Publication number
JP2022512796A
JP2022512796A JP2021522350A JP2021522350A JP2022512796A JP 2022512796 A JP2022512796 A JP 2022512796A JP 2021522350 A JP2021522350 A JP 2021522350A JP 2021522350 A JP2021522350 A JP 2021522350A JP 2022512796 A JP2022512796 A JP 2022512796A
Authority
JP
Japan
Prior art keywords
ifn
subject
genes
biological sample
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021522350A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020084591A5 (enExample
Inventor
セサロニ，マッテオ
シェブリエ，マーク
ジョーダン，ジャラット
シュライター，ジェシカ
Original Assignee
ヤンセン バイオテツク，インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオテツク，インコーポレーテツド filed Critical ヤンセン バイオテツク，インコーポレーテツド
Publication of JP2022512796A publication Critical patent/JP2022512796A/ja
Publication of JPWO2020084591A5 publication Critical patent/JPWO2020084591A5/ja
Priority to JP2024090820A priority Critical patent/JP2024119889A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2539/00—Reactions characterised by analysis of gene expression or genome comparison
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2545/00—Reactions characterised by their quantitative nature
    • C12Q2545/10—Reactions characterised by their quantitative nature the purpose being quantitative analysis
    • C12Q2545/114—Reactions characterised by their quantitative nature the purpose being quantitative analysis involving a quantitation step
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Primary Health Care (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
JP2021522350A 2018-10-26 2019-10-25 Ｉ型インターフェロンシグネチャー及び使用方法 Withdrawn JP2022512796A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024090820A JP2024119889A (ja) 2018-10-26 2024-06-04 Ｉ型インターフェロンシグネチャー及び使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862751019P 2018-10-26 2018-10-26
US62/751,019 2018-10-26
PCT/IB2019/059178 WO2020084591A1 (en) 2018-10-26 2019-10-25 Type i interferon signatures and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024090820A Division JP2024119889A (ja) 2018-10-26 2024-06-04 Ｉ型インターフェロンシグネチャー及び使用方法

Publications (2)

Publication Number Publication Date
JP2022512796A true JP2022512796A (ja) 2022-02-07
JPWO2020084591A5 JPWO2020084591A5 (enExample) 2022-11-01

Family

ID=70328348

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021522350A Withdrawn JP2022512796A (ja) 2018-10-26 2019-10-25 Ｉ型インターフェロンシグネチャー及び使用方法
JP2024090820A Pending JP2024119889A (ja) 2018-10-26 2024-06-04 Ｉ型インターフェロンシグネチャー及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024090820A Pending JP2024119889A (ja) 2018-10-26 2024-06-04 Ｉ型インターフェロンシグネチャー及び使用方法

Country Status (10)

Country Link
US (1) US12009079B2 (enExample)
EP (1) EP3873523A4 (enExample)
JP (2) JP2022512796A (enExample)
KR (1) KR20210084528A (enExample)
CN (1) CN113692287A (enExample)
CA (1) CA3117102A1 (enExample)
EA (1) EA202191133A1 (enExample)
IL (1) IL282479A (enExample)
MA (1) MA54085A (enExample)
WO (1) WO2020084591A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114836534A (zh) * 2021-06-08 2022-08-02 中国医学科学院北京协和医院 Samd9l基因突变作为i型干扰素病诊断的标志物及其应用
CA3266513A1 (en) 2022-09-14 2024-03-21 Viatris Asia Pacific Pte. Ltd. S1P1 RECEPTOR MODULATORS INTENDED FOR USE IN THE TREATMENT OF TYPE 1 IFN-MEDICATED DISEASES
WO2024100139A1 (en) * 2022-11-09 2024-05-16 Merck Patent Gmbh Use of ifn-i activity as a biomarker for tlr inhibitor treatment
WO2024173764A1 (en) * 2023-02-16 2024-08-22 Alumis Inc. Methods of treating hidradenitis suppurativa
EP4665349A1 (en) * 2023-02-16 2025-12-24 Alumis Inc. Methods of treating dermatological disorders
WO2024201091A1 (en) * 2023-03-27 2024-10-03 Institut National de la Santé et de la Recherche Médicale A gene signature for diagnosing stimulator of interferon genes (sting)-associated vasculopathy with onset in infancy (savi)
WO2024216160A1 (en) * 2023-04-14 2024-10-17 Arc Research Institute Methods and compositions for using peli2 as a biomarker
CN117138038A (zh) * 2023-09-21 2023-12-01 北京大学 一种预防、治疗或缓解椎体后纵韧带骨化症的药物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010512315A (ja) * 2006-12-06 2010-04-22 メディミューン，エルエルシー インターフェロンα誘導性薬力学的マーカー
WO2012054284A2 (en) * 2010-10-20 2012-04-26 University Of Tennessee Research Foundation Interferon gene signature and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0613387A2 (pt) * 2005-07-08 2011-01-11 Biogen Idec Inc anticorpo isolado ou fragmento de ligação de antìgeno deste e o seu uso, polinucleotìdeo isolado, composição, vetor, célula hospedeira, anticorpo anti-sp35 e método para a produção do mesmo, polipeptìdeo isolado, método in vitro para redução da inibição do crescimento axonal e método in vitro para inibição do crescimento do colapso do cone
EP2068924A4 (en) * 2007-05-03 2011-07-20 Medimmune Llc INTERFERON ALPHA INDUCED PHARMACODYNAMIC MARKERS
EP2419727A1 (en) * 2009-04-14 2012-02-22 Schering Corporation Interferon-alfa sensitivity biomarkers
CA2834203A1 (en) * 2011-04-26 2012-11-01 Genentech, Inc. Compositions and method for treating autoimmune diseases
RU2013157177A (ru) * 2011-05-25 2015-06-27 МЕДИММЬЮН, ЭлЭлСи Способы лечения системной красной волчанки, склеродермии и миозита
WO2013101771A2 (en) * 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
KR102320059B1 (ko) * 2012-06-13 2021-11-01 아스트라제네카 아베 항-i형 인터페론 수용체(ifnar) 항체에 대한 고정 투여 계획
US10689441B2 (en) * 2013-12-06 2020-06-23 Novimmune Sa Anti—TLR4 antibodies and methods of use thereof
TWI713453B (zh) * 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
US10689703B2 (en) * 2015-04-27 2020-06-23 National Jewish Health Methods of identifying and treating subjects having acute respiratory distress syndrome
CN109963870B (zh) * 2016-06-08 2023-07-28 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
EP3947448A4 (en) * 2019-04-04 2023-02-01 Janssen Biotech, Inc. PROCEDURE FOR ADMINISTRATION OF AN ANTI-IFN ALPHA/OMEGA ANTIBODY

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010512315A (ja) * 2006-12-06 2010-04-22 メディミューン，エルエルシー インターフェロンα誘導性薬力学的マーカー
WO2012054284A2 (en) * 2010-10-20 2012-04-26 University Of Tennessee Research Foundation Interferon gene signature and methods of use thereof

Also Published As

Publication number Publication date
JP2024119889A (ja) 2024-09-03
IL282479A (en) 2021-06-30
CA3117102A1 (en) 2020-04-30
CN113692287A (zh) 2021-11-23
EP3873523A1 (en) 2021-09-08
US20200131241A1 (en) 2020-04-30
EA202191133A1 (ru) 2021-07-12
KR20210084528A (ko) 2021-07-07
WO2020084591A1 (en) 2020-04-30
US12009079B2 (en) 2024-06-11
MA54085A (fr) 2021-09-15
EP3873523A4 (en) 2022-08-10

Similar Documents

Publication Publication Date Title
US12009079B2 (en) Type I interferon signatures and methods of use
RU2527068C2 (ru) Фармакодинамические маркеры, индуцированные интерфероном альфа
JP5727484B2 (ja) Ｉ型インターフェロン診断法
CA2988674C (en) Detection of chromosome interactions
AU2009240021B2 (en) Antiviral therapy
JP2015504430A (ja) Ｉｌ−７アンタゴニスト及びｐｓａ応答又は非応答対立遺伝子を用いた乾癬性関節炎（ｐｓａ）を治療する方法
US20200103418A1 (en) Diagnostic and therapeutic methods for irak4-mediated disorders and conditions
JP2011511804A (ja) 疾患マーカーおよびその使用
US20140135225A1 (en) Biomarkers for disease activity and clinical manifestations systemic lupus erythematosus
EP3052193B1 (en) Biomarkers for systemic lupus erythematosus disease activity, and intensity and flare
TW201307845A (zh) 預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法
AU2014329535A1 (en) Biomarkers for systemic lupus erythematosus disease activity, and intensity and flare
AlFadhli et al. Th‐17 related regulatory network in the pathogenesis of Arab patients with systemic lupus erythematosus and lupus nephritis
EP3180446A1 (en) Therapy selection for psoriasis and psoriatic arthritis
JP2023549872A (ja) ステロイド節約
EA048244B1 (ru) Сигнатуры интерферона типа i и способы их применения
TW201343176A (zh) 使用ｉｌ－１７拮抗劑治療乾癬性關節炎之方法
WO2013117751A2 (en) Methods related to treatment of inflammatory diseases and disorders
CN119866215A (zh) 用于治疗第1型ifn介导疾病的s1p1受体调节剂
Li Identification and characterization of susceptibility genes and dysregulated signaling pathways in Sjögren's syndrome
de Bono et al. Thomas Dörner, Yoshiya Tanaka, 2 Michelle A Petri, 3 Josef S Smolen, 4 Daniel J Wallace, 5 Ernst R Dow, 6 Richard E Higgs, 6 Guilherme Rocha, 6 Brenda Crowe, 6 Robert J Benschop, 6 Nicole L Byers, 6 Maria E Silk, 6
Sutherland Optimization of circulating miRNA library preparation for next-generation sequencing and an exploratory pharmacogenomics investigation of psoriatic arthritis patients treated with IL-12/23 or IL-17 inhibitors
HK40020002A (en) Diagnostic and therapeutic methods for irak4-mediated disorders and conditions
Santegoetsa et al. AN AutOIMMuNe PHeNOtyPe IN VuLVAr LICHeN SCLerOSuS ANd LICHeN PLANuS: A tH1 reSPONSe ANd HIgH LeVeLS OF MICrOrNA-155
HK1140406A (en) Interferon alpha-induced pharmacodynamic markers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240228

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20240627